Wells Fargo
ABVX

Wells Fargo’s Abivax ABVX Stock Holding History

Wells Fargo’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$322K Buy
2,896
+2,159
+293% +$256K ﹤0.01% 4393
2025
Q4 		$99.4K Buy
737
+20
+3% +$2.18K ﹤0.01% 5390
2025
Q3 		$60.9K Buy
+717
New +$44K ﹤0.01% 5496

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Wells Fargo's ABVX Position: Q1 2026 in Review

Wells Fargo increased its Abivax (ABVX) stake by 293% in Q1 2026, buying an estimated $256K and bringing the position to 2,896 shares worth $322K. The position accounts for ﹤0.01% of the portfolio, ranked #4393.

Wells Fargo first reported a position in ABVX in Q3 2025 and has held it in 3 quarters since. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Wells Fargo held 2,896 shares of Abivax worth $322K as of Q1 2026.
  • Wells Fargo bought 2,159 Abivax shares in Q1 2026, an estimated $256K.
  • Abivax made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4393 holding.
  • Wells Fargo first reported a position in Abivax in Q3 2025 and has held it in 3 quarters since.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.